EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Polymorphic ventricular tachycardia with mutation in KCNJ2: case report

Cuizhen Zhou, Juan Chen, Cuilan Hou, Tingting Xiao, Li Zhang

Frontiers in Cardiovascular Medicine · 16.06.2026 · 13

DOI: 10.3389/fcvm.2026.1839923 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 16.06.2026. Verfasst von Cuizhen Zhou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Polymorphic ventricular tachycardia (VT), particularly in the absence of structural heart disease, has a strong genetic foundation primarily rooted in mutations affecting cardiac ion channels and associated regulatory proteins. Here, we report two patients with polymorphic VT harboring potassium channel subfamily J member 2 (KCNJ2) gene mutations. The first case is a 13-year-old girl presenting with periodic paralysis, polymorphic VT, and a prolonged QT interval. She was sequentially treated with metoprolol, verapamil, amiodarone, moricizine, and mexiletine, along with three radiofrequency catheter ablation sessions, but the therapeutic effect was unsatisfactory. Genetic testing revealed a de novo c.406T > C (p.S136P) variant in the KCNJ2 gene. During a 10-year follow-up period, she never experienced syncope. The second patient is a 5-year-old boy presenting with thumb adduction, polymorphic VT, and a prolonged QT interval. He was treated sequentially with metoprolol and flecainide, and his premature ventricular contraction burden decreased significantly after flecainide therapy. Genetic testing identified a de novo c.652C > T (p.A218T) variant in the KCNJ2 gene. This case report updates our understanding of KCNJ2 gene mutations. Arrhythmias due to KCNJ2 mutations respond poorly to antiarrhythmic drugs, but flecainide may be a promising therapeutic option. Arrhythmias associated with KCNJ2 mutations tend to have a more benign clinical course, but identifying mutation carriers at risk of life-threatening arrhythmias remains challenging.

Schlagwörter

Stichwörter der Autor:innen

Andersen-Tawil syndromeKCNJ2LQTScase reportpolymorphic ventricular tachycardia

Autor:innen und Institutionen

  • Department of Cardiology, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

Zitieren

APA

Zhou, C., Chen, J., Hou, C., Xiao, T., & Zhang, L. (2026). Polymorphic ventricular tachycardia with mutation in KCNJ2: case report. Frontiers in Cardiovascular Medicine, 13. https://doi.org/10.3389/fcvm.2026.1839923

Vancouver

Zhou C, Chen J, Hou C, Xiao T, Zhang L. Polymorphic ventricular tachycardia with mutation in KCNJ2: case report. Frontiers in Cardiovascular Medicine. 2026;13. doi:10.3389/fcvm.2026.1839923

BibTeX
@article{Zhou2026,
  author = {Zhou, Cuizhen and Chen, Juan and Hou, Cuilan and Xiao, Tingting and Zhang, Li},
  title = {Polymorphic ventricular tachycardia with mutation in KCNJ2: case report},
  journal = {Frontiers in Cardiovascular Medicine},
  year = {2026},
  volume = {13},
  doi = {10.3389/fcvm.2026.1839923}
}
Kostenlos starten →